SG11201608438YA - Analogs of 4h-pyrazolo[1,5-α]benzimidazole compounds as parp inhibitors - Google Patents
Analogs of 4h-pyrazolo[1,5-α]benzimidazole compounds as parp inhibitorsInfo
- Publication number
- SG11201608438YA SG11201608438YA SG11201608438YA SG11201608438YA SG11201608438YA SG 11201608438Y A SG11201608438Y A SG 11201608438YA SG 11201608438Y A SG11201608438Y A SG 11201608438YA SG 11201608438Y A SG11201608438Y A SG 11201608438YA SG 11201608438Y A SG11201608438Y A SG 11201608438YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolo
- analogs
- parp inhibitors
- benzimidazole compounds
- benzimidazole
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410144173.0A CN104974161B (en) | 2014-04-10 | 2014-04-10 | The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor |
| CN201510113090 | 2015-03-13 | ||
| PCT/CN2015/075363 WO2015154630A1 (en) | 2014-04-10 | 2015-03-30 | Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608438YA true SG11201608438YA (en) | 2016-11-29 |
Family
ID=54287319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608438YA SG11201608438YA (en) | 2014-04-10 | 2015-03-30 | Analogs of 4h-pyrazolo[1,5-α]benzimidazole compounds as parp inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9856262B2 (en) |
| EP (1) | EP3130592B1 (en) |
| JP (1) | JP6359175B2 (en) |
| KR (1) | KR101921486B1 (en) |
| CN (1) | CN106459057B (en) |
| AU (1) | AU2015245786B2 (en) |
| BR (1) | BR112016023397B1 (en) |
| CA (1) | CA2944801C (en) |
| DK (1) | DK3130592T3 (en) |
| ES (1) | ES2754590T3 (en) |
| HU (1) | HUE047410T2 (en) |
| IL (1) | IL248258B (en) |
| MX (1) | MX368496B (en) |
| NZ (1) | NZ725165A (en) |
| PL (1) | PL3130592T3 (en) |
| PT (1) | PT3130592T (en) |
| RU (1) | RU2672722C2 (en) |
| SA (1) | SA516380051B1 (en) |
| SG (1) | SG11201608438YA (en) |
| TW (1) | TWI671301B (en) |
| WO (1) | WO2015154630A1 (en) |
| ZA (1) | ZA201607736B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974161B (en) * | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor |
| CN108137598B (en) | 2015-09-30 | 2021-02-12 | 湖北生物医药产业技术研究院有限公司 | Salt form and crystal form of 4H-pyrazolo [1, 5-alpha ] benzimidazole compound, and preparation method and intermediate thereof |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018197401A1 (en) | 2017-04-27 | 2018-11-01 | Bayer Animal Health Gmbh | New bicyclic pyrazole derivatives |
| CN115028641B (en) * | 2022-07-19 | 2024-05-28 | 湖南大学 | A method for synthesizing 5,8-difunctional substituted imidazo[1,2-a]pyrazine compounds using cobalt catalyst |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025056690A1 (en) | 2023-09-12 | 2025-03-20 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4 |
| CN116969954B (en) * | 2023-09-21 | 2023-11-28 | 广东省农业科学院农业质量标准与监测技术研究所 | Tricyclic fused heterocyclic compounds containing lactam and application thereof |
| TW202530228A (en) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ras inhibitors |
| CN117534677B (en) * | 2024-01-09 | 2024-03-12 | 广东省农业科学院农业质量标准与监测技术研究所 | Imine-containing tricyclic fused heterocyclic compound and application thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916051A (en) * | 1987-04-07 | 1990-04-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| MY143499A (en) * | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
| EP1973909A2 (en) * | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
| WO2007144669A1 (en) | 2006-06-15 | 2007-12-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp) |
| EP2069351B1 (en) | 2006-06-20 | 2015-10-28 | AbbVie Inc. | Pyrazoloquinazolinones as parp inhibitors |
| GB0701273D0 (en) | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| PT2656843E (en) | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
| PT2844659T (en) * | 2012-05-04 | 2016-08-31 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| EP2666775A1 (en) * | 2012-05-21 | 2013-11-27 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
| CA2873723A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| IN2015MN00002A (en) * | 2012-07-09 | 2015-10-16 | Lupin Ltd | |
| CN103570725B (en) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | Piperazidinoltriazole compound as well as preparation method and application thereof |
| RU2654216C2 (en) * | 2012-08-08 | 2018-05-17 | Мерк Патент Гмбх | (aza-)isoquinoline derivatives |
| CN104974161B (en) | 2014-04-10 | 2019-11-01 | 湖北生物医药产业技术研究院有限公司 | The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor |
-
2015
- 2015-03-30 NZ NZ725165A patent/NZ725165A/en unknown
- 2015-03-30 BR BR112016023397-2A patent/BR112016023397B1/en active IP Right Grant
- 2015-03-30 EP EP15777444.9A patent/EP3130592B1/en active Active
- 2015-03-30 PT PT157774449T patent/PT3130592T/en unknown
- 2015-03-30 PL PL15777444T patent/PL3130592T3/en unknown
- 2015-03-30 MX MX2016013265A patent/MX368496B/en active IP Right Grant
- 2015-03-30 RU RU2016144202A patent/RU2672722C2/en active
- 2015-03-30 CA CA2944801A patent/CA2944801C/en active Active
- 2015-03-30 CN CN201580017657.1A patent/CN106459057B/en active Active
- 2015-03-30 DK DK15777444T patent/DK3130592T3/en active
- 2015-03-30 JP JP2017504223A patent/JP6359175B2/en active Active
- 2015-03-30 HU HUE15777444A patent/HUE047410T2/en unknown
- 2015-03-30 ES ES15777444T patent/ES2754590T3/en active Active
- 2015-03-30 US US15/302,588 patent/US9856262B2/en active Active
- 2015-03-30 AU AU2015245786A patent/AU2015245786B2/en active Active
- 2015-03-30 KR KR1020167031520A patent/KR101921486B1/en active Active
- 2015-03-30 WO PCT/CN2015/075363 patent/WO2015154630A1/en not_active Ceased
- 2015-03-30 SG SG11201608438YA patent/SG11201608438YA/en unknown
- 2015-04-08 TW TW104111236A patent/TWI671301B/en active
-
2016
- 2016-10-09 IL IL248258A patent/IL248258B/en active IP Right Grant
- 2016-10-10 SA SA516380051A patent/SA516380051B1/en unknown
- 2016-11-09 ZA ZA2016/07736A patent/ZA201607736B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287517A (en) | Benzimidazole compounds as c-kit inhibitors | |
| SG11201608438YA (en) | Analogs of 4h-pyrazolo[1,5-α]benzimidazole compounds as parp inhibitors | |
| IL256808A (en) | Heteroaryl derivatives as parp inhibitors | |
| SMT202200250T1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| ZA201801032B (en) | Bicyclic compounds as atx inhibitors | |
| IL254318B (en) | Benzimidazole derivatives as bromodomain inhibitors | |
| IL255570A (en) | Bicyclic compounds as atx inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL251780A0 (en) | New compounds as nik inhibitors | |
| ZA201804688B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| IL266745A (en) | Benzodiazolium compounds as enac inhibitors | |
| ZA201701644B (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| IL254476A0 (en) | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| IL256226A (en) | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors | |
| IL266121A (en) | Substituted quinoxaline derivatives as inhibitors of pfkfb |